Design and synthesis of peptides involved in the inhibition of influenza virus infection
Creators: name: Scala, Maria Carmina
Publisher: name: Universita degli studi di Salerno
Year: 2017
Subjects: subject: CHIM/08 CHIMICA FARMACEUTICA
subject: Bovine lactoferrin
subject: Influenza virus
subject: Peptides

description: 2014 - 2015
description: The main purpose of the present research project was the identification of peptide capable of exercising potent anti-influenza activity. We identified bovine lactoferrin (bLf) as drug target, a multifunctional glycoprotein that plays an important role in innate immunity against infections, including influenza. Previously, by protein-protein docking calculations, it was demonstrated that different loops of bLf C-lobe, corresponding to the sequences 418-429 (SKHSSLDCVLRP, 1), 506-522 (AGDDQGLDKCVPNSKEK, 2), 552-563 (NGESSADWAKN, 3), 441-454 (TNGESTADWAKN, 4), 478-500 (KANEGLTWNSLKDK, 5), 552-563 (TGSCAFDEFFSQSCAPGADPKSR, 6), 619-630 (GKNGKNCPDKFC, 7), 633-638 (KSETKN, 8) and 642-659 (NDNTECLAKLGGRPTYEE, 9) can contribute to the binding to HA. These peptides were synthesized and tested for their ability to inhibit hemagglutination and cell infection. The results showed that peptide 1 binds to HA and neutralizes hemagglutination and cell infection of different strains of Influenza virus with a very high potency. Therefore, we considered peptide 1 as lead compound for the development of novel compounds with improved anti-influenza activity. To identify the shortest amino acid sequence needed for the peptide activity, we designed a new small library of peptides through addition and deletion of four amino acid residues at both the N- and C-terminals of this fragment (peptide 10-17). Three tetrapeptides, 14 (VLRP), 15 (SLDC) and 17 (SKHS), retained the inhibitory potency of the fragment 418-429, inhibiting the Influenza virus hemagglutination and cell infection in a concentration range of femto- to picomolar. Therefore, focused on peptide 14, we evaluated the importance of the net positive charge (Arg428) for the biological activity (peptides 18-23). We then decided to apply to peptides 15 and 17 L-Alanine scanning approach, a classical chemical approach to check the relevance of side chains of each aminoacidic residue in the interaction with the target molecule (peptides 24-31). Finally, in order to improve the pharmacokinetic properties of biologically active tetrapeptides 15 and 17, we synthetized N-methyl peptides (peptides 32-41) and peptoid analogues (compound 42-51). We demonstrated that no compound was able to inhibit HA activity in a greater extent of peptides 15 and 17. NMR spectroscopy analysis performed on compounds 1 showed a global turn conformation for this peptide and hypothesized the preferred bioactive conformation of our tetrapeptides. Moreover, based on conformational analysis, we tried to stabilize 3D structure of peptide 1, S[KHSSLD]CVLRP, through cyclization of the peptide backbone. To synthesize this cyclic peptide, we used the allyl ester (OAll) as orthogonal protecting group for aspartic acid side-chain. Surprisingly, our approach to synthesize the peptide mentioned above, failed completely. In particular, after the deprotection of aspartic acid Fmoc group by piperidine (20% v/v in DMF) for 30 min at room temperature, the formation of unexpected side-products was observed. Therefore, we studied this phenomenon and tried to obtain the desidered sequence with different approaches. We hypothesized that the aspartimide and pyperidinil derivative formation is conformation-dependent. Finally, we synthetized the desidered peptide, using as β-protecting group of aspartic acid and lysine, β-2-phenylisopropyl ester and methoxytrityl, respectively. LC-MS analysis confirmed the presence of the desired cyclic peptide. [edited by author]